Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

NCT03988582 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

EBV Lymphomas
EBV-associated Malignancies

Interventions

BIOLOGICAL: EBV-specific T-cells

Sponsor

Memorial Sloan Kettering Cancer Center